The Latest Breaking News from Precision BioSciences

Precision BioSciences Inc (NASDAQ:DTIL) has entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis AG (NYSE:NVS)  Precision will develop a custom ARCUS nuclease that will be designed to insert, in vivo, a therapeutic transgene at a "safe harbor" location in the genome as a potential one-time…

BMO Capital Markets initiated the coverage on Precision BioSciences Inc (NASDAQ:DTIL) with an Outperform rating and a price target of $7. The analyst said the thesis is based on: The company's proprietary gene-editing platform, whose mechanism is differentiated in a CRISPR-dominated space, offers several advantages. A diversified pipeline. Asymmetric risk/reward skewed to the upside.…

Precision BioSciences (NASDAQ:DTIL) brought in sales totaling $6.34 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 97.62%, resulting in a loss of $22.29 million.

  Precision BioSciences (NASDAQ:DTIL) reported its Q4 earnings results on Tuesday, March 15, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Precision BioSciences (NASDAQ:DTIL) is set to give its latest quarterly earnings report on Tuesday, 2022-03-15. Here's what investors need to know before the announcement. Analysts estimate that Precision BioSciences will report an earnings per share (EPS) of $-0.47.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported clinical data in a patient with Secondary Progressive Multiple Sclerosis (SPMS) following six months of treatment with intranasally administered foralumab. In addition to being well-tolerated, both biological and clinical improvements were seen in the patient using Tiziana's immunotherapy technology, which overcame the challenge of delivering foralumab…